First, a randomized controlled trial (RCT) [28] found that treatment with melatonin increased BMD while the same result was observed in an animal study [29], another RCT [30] indicated that GH treatment in postmenopausal osteoporosis reduced the fracture incidence by 28% during the 10 years follow-up, and Tritos’ analysis [31] also suggested that GH treatment was associated with decreased fracture risk in adults. This evidence concerns the gene GH1 and osteoporosis.